Lancovutide

Drug Profile

Lancovutide

Alternative Names: 2622U90; Duramycin; Moli 1901; PA 48009

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Lantibio
  • Developer AOP Orphan Pharmaceuticals AG; Lantibio
  • Class Expectorants; Peptides
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cystic fibrosis; Dry eyes

Most Recent Events

  • 16 Sep 2009 Pharmacokinetics data from a phase I trial in Cystic fibrosis presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 08 Mar 2007 Results from a phase II clinical trial in patients with Cystic fibrosis have been added to the adverse events and Respiratory disoders therapeutic trials sections
  • 17 Jan 2006 Phase-II clinical trials in Cystic fibrosis in Austria (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top